| NCT06576843 | INDV-6001 Multiple-Dose Pharmacokinetic Study | Phase 2 | Completed | Sep 17, 2024 | Jan 21, 2026 (actual) |
| NCT04995029 | Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users | Phase 4 | Completed | Oct 26, 2021 | Jun 26, 2024 (actual) |
| NCT05878210 | Evaluating the SUBLOCADE Treatment Exit Strategy | Not listed | Completed | Nov 24, 2023 | May 9, 2025 (actual) |
| NCT06384157 | Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use Disorder | Phase 2 | Completed | Jun 10, 2024 | Sep 29, 2025 (actual) |
| NCT05860959 | SUBLOCADE Long-term Outcomes | Not listed | Completed | Aug 31, 2023 | Aug 31, 2025 (actual) |
| NCT04060654 | SUBLOCADE Rapid Initiation Extension Study | Phase 4 | Completed | Oct 21, 2019 | May 15, 2020 (actual) |
| NCT03993392 | SUBLOCADE Rapid Initiation Study | Phase 4 | Completed | Aug 29, 2019 | Dec 26, 2019 (actual) |
| NCT03747341 | Buprenorphine-Fentanyl Interaction Study | Phase 1 | Completed | Mar 22, 2018 | Jan 4, 2019 (actual) |
| NCT05974046 | Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male Participants | Phase 1 | Completed | Jul 10, 2023 | Jul 21, 2023 (actual) |
| NCT05704543 | Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection Locations | Phase 4 | Completed | Mar 1, 2023 | Nov 1, 2023 (actual) |
| NCT04976855 | Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder | Phase 1 | Completed | Aug 17, 2022 | Jul 5, 2023 (actual) |
| NCT05694533 | Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults | Phase 1 | Completed | Mar 16, 2023 | Apr 6, 2023 (actual) |
| NCT04413552 | INDV-2000 First in Human | Phase 1 | Completed | Jul 6, 2020 | Apr 13, 2021 (actual) |
| NCT01075971 | Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED) | Phase 2 | Completed | 2005-09 | 2005-11 (actual) |
| NCT00756353 | Survey of Buprenorphine Use Among "Out of Care" Population in France (P04933)(COMPLETED) | Not listed | Completed | 2006-06 | 2006-12 (actual) |
| NCT00684073 | Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) | Phase 4 | Completed | 2007-07 | 2007-12 (actual) |
| NCT00723697 | Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED) | Not listed | Completed | 2007-05 | 2010-02 (actual) |
| NCT04577144 | An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long Term | Not listed | Terminated | Sep 20, 2020 | Jan 11, 2021 (actual) |
| NCT03978832 | Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral Risperidone | Phase 4 | Completed | Jun 28, 2019 | May 12, 2020 (actual) |
| NCT03752528 | Evaluation of Long-term Buprenorphine Plasma Exposure | Not listed | Completed | Feb 19, 2019 | Jul 18, 2019 (actual) |
| NCT03604861 | An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery | Not listed | Completed | 2015-08 | 2019-03 (actual) |
| NCT03715634 | Study of a Novel Subcutaneous Depot Formulation of Buprenorphine | Phase 1 | Completed | Sep 20, 2017 | Jun 7, 2018 (actual) |
| NCT02896296 | Open-Label Treatment Extension Study | Phase 3 | Completed | Aug 17, 2016 | Aug 23, 2017 (actual) |
| NCT02109562 | Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients | Phase 3 | Completed | 2014-04 | 2014-11 (actual) |
| NCT01677377 | Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy | Phase 2 | Completed | 2012-08 | 2013-04 (actual) |
| NCT02203838 | Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia | Phase 3 | Completed | 2014-06 | 2016-09 (actual) |
| NCT02044094 | Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder | Phase 2 | Completed | 2013-11 | 2014-07 (actual) |
| NCT02510014 | Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder | Phase 3 | Completed | Jul 27, 2015 | Jan 31, 2017 (actual) |
| NCT01738503 | Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects | Phase 2 | Completed | 2012-10 | 2014-05 (actual) |
| NCT02357901 | Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine | Phase 3 | Completed | Jan 28, 2015 | Apr 29, 2016 (actual) |
| NCT03058237 | A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers | 1 | Completed | Jan 24, 2017 | Jul 5, 2017 (actual) |
| NCT00637000 | Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone | Phase 2 | Completed | 2008-03 | 2008-09 (actual) |
| NCT02038790 | Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population | Phase 4 | Completed | 2013-11 | 2013-11 (actual) |
| NCT00725608 | Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444) | Not listed | Completed | 2008-05 | 2011-04 (actual) |
| NCT02559973 | Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder | Phase 1 | Completed | 2015-09 | 2016-02 (actual) |
| NCT02687984 | PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia | Phase 1 | Completed | 2016-02 | 2016-05 (actual) |
| NCT02511886 | A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder | Phase 2 | Completed | 2015-09 | 2016-01 (actual) |
| NCT01582347 | Transfer of Subjects From Subutex/Suboxone to RBP-6300 | Phase 2 | Completed | 2012-03 | 2012-11 (actual) |
| NCT03002961 | Single Ascending Dose Study of RBP-6000 | Phase 1 | Completed | 2012-07 | 2013-02 (actual) |
| NCT01846455 | Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects | Phase 4 | Completed | 2012-09 | 2013-04 (actual) |
| NCT00605033 | A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) | Phase 4 | Completed | 2008-03 | 2009-04 (actual) |
| NCT01846481 | A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse | Phase 2 | Completed | 2013-04 | 2013-06 (actual) |
| NCT00838396 | A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux Disease | Phase 2 | Completed | 2005-10 | 2006-08 (actual) |
| NCT02768649 | Single Ascending Dose Study of RBP-7000 | Phase 1 | Completed | 2011-04 | 2012-02 (actual) |
| NCT02765867 | Single-dose, Study of RBP-6000 in Opioid Dependent Individuals | Phase 1 | Completed | 2010-11 | 2011-05 (actual) |
| NCT02765555 | First in Man Study of Safety, Tolerability and PK Profile of RBP-7000 | Phase 1 | Completed | 2010-03 | 2010-09 (actual) |
| NCT00901875 | Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan | Phase 4 | Completed | 2009-03 | 2009-11 (actual) |
| NCT00955162 | Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") | Phase 4 | Completed | 2009-08 | 2010-05 (actual) |
| NCT00279565 | Buprenorphine Versus Methadone Maintenance in Hepatitis C Patients Receiving Peg-Intron and Rebetol (Study P04279)(TERMINATED) | Phase 4 | Terminated | 2005-08 | 2007-02 (actual) |
| NCT00640835 | Safety and Tolerability of Buprenorphine/Naloxone Film Strips | Phase 2 | Completed | 2008-02 | 2008-10 (actual) |
